Table 1.
Patient clinical and demographic data of combined FAST and PARTNERS-HF trials used for the present analysis.
| Total (n = 775) | |
|---|---|
| Mean age (SD) | 69 (11) |
| Male gender | 524 (68%) |
| Ethnic origin | |
| Caucasian | 655 (85%) |
| African American | 85 (11%) |
| Other/Unknown | 35 (5%) |
| NYHA | |
| I | 9 (1%) |
| II | 59 (8%) |
| III | 674 (87%) |
| IV | 33 (4%) |
| Ischemic | 485 (63%) |
| Coronary artery disease | 524 (68%) |
| Myocardial infarction | 360 (46%) |
| Hypertension | 552 (71%) |
| Diabetes | 324 (42%) |
| History of AF | 219 (28%) |
| LVEF ≤35%a | 676 (100%) |
| Baseline medications | |
| ACE/ARB | 641 (83%) |
| Beta-blockers | 696 (90%) |
| Diuretics | 642 (83%) |
| Digoxin | 279 (36%) |
| Aldosterone antagonist | 257 (33%) |
| Hydralazine | 44 (6%) |
| Nitrates | 215 (28%) |
| Anti-arrhythmic drugs | 138 (18%) |
| Warfarin | 183 (24%) |
a
LVEF was only available for 676 patients.